The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model

Helen M. Dodds, Peter J. Tobin, Clinton F. Stewart, Pam Cheshire, Suzan Hanna, Peter J Houghton, Laurent P. Rivory

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The anticancer drug irinotecan (CPT-11) is activated to the potent topoisomerase I inhibitor, SN-38 (7-ethyl-10-hydroxy-camptothecin), by esterases. SN-38 is in turn conjugated to the inactive SN-38 glucuronide (SN-38G). The reverse reaction is mediated by β-glucuronidases. Hence, production of SN-38 may occur through either pathway. In this study we conducted in vitro studies to examine these two reactions in neuroblastoma xenograft tumors (NB1691) and compared the rates of SN-38 production with those observed in the liver and plasma of the host SCID (severe-combined immunodeficient) mice. The rate of formation of SN-38 from CPT-11 by esterases slowed considerably during a 60-min incubation, consistent with the known deacylation-limited nature of this reaction. For xenograft tumor tissue, Km and Vmax values of 1.6 μM and 4.4 pmol/min/mg of protein, respectively, were observed. By comparison, these parameters were estimated to be 6.9 μM and 9.4 pmol/min/mg for mouse liver and 2.1 μM and 40.0 pmol/min/mg for mouse plasma, respectively. The formation of SN-38 from SN-38G was very pronounced in both liver and xenograft tumor tissue, in which it was nonsaturable (0.125-50 μM) and time-independent (0-60 min). The derived values of Vmax/Km were 0.65 μl/min/mg for the tumor and 2.12 μl/min/mg for the liver preparations. Microdialysate experiments revealed the concentrations of SN-38G and CPT-11 in tumor to be comparable. At equal substrate concentrations, production of SN-38 from SN-38G in tumor extracts was comparable with that from CPT-11. Therefore, reactivation of SN-38 in the tumor by β-glucuronidases may represent an important route of tumor drug activation for CPT-11.

Original languageEnglish (US)
Pages (from-to)649-655
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume303
Issue number2
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

irinotecan
Glucuronidase
Heterografts
Neoplasms
Liver
Esterases

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. / Dodds, Helen M.; Tobin, Peter J.; Stewart, Clinton F.; Cheshire, Pam; Hanna, Suzan; Houghton, Peter J; Rivory, Laurent P.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 303, No. 2, 01.11.2002, p. 649-655.

Research output: Contribution to journalArticle

Dodds, Helen M. ; Tobin, Peter J. ; Stewart, Clinton F. ; Cheshire, Pam ; Hanna, Suzan ; Houghton, Peter J ; Rivory, Laurent P. / The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. In: Journal of Pharmacology and Experimental Therapeutics. 2002 ; Vol. 303, No. 2. pp. 649-655.
@article{7208472a1bfb4a26b42b8e59526577fe,
title = "The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model",
abstract = "The anticancer drug irinotecan (CPT-11) is activated to the potent topoisomerase I inhibitor, SN-38 (7-ethyl-10-hydroxy-camptothecin), by esterases. SN-38 is in turn conjugated to the inactive SN-38 glucuronide (SN-38G). The reverse reaction is mediated by β-glucuronidases. Hence, production of SN-38 may occur through either pathway. In this study we conducted in vitro studies to examine these two reactions in neuroblastoma xenograft tumors (NB1691) and compared the rates of SN-38 production with those observed in the liver and plasma of the host SCID (severe-combined immunodeficient) mice. The rate of formation of SN-38 from CPT-11 by esterases slowed considerably during a 60-min incubation, consistent with the known deacylation-limited nature of this reaction. For xenograft tumor tissue, Km and Vmax values of 1.6 μM and 4.4 pmol/min/mg of protein, respectively, were observed. By comparison, these parameters were estimated to be 6.9 μM and 9.4 pmol/min/mg for mouse liver and 2.1 μM and 40.0 pmol/min/mg for mouse plasma, respectively. The formation of SN-38 from SN-38G was very pronounced in both liver and xenograft tumor tissue, in which it was nonsaturable (0.125-50 μM) and time-independent (0-60 min). The derived values of Vmax/Km were 0.65 μl/min/mg for the tumor and 2.12 μl/min/mg for the liver preparations. Microdialysate experiments revealed the concentrations of SN-38G and CPT-11 in tumor to be comparable. At equal substrate concentrations, production of SN-38 from SN-38G in tumor extracts was comparable with that from CPT-11. Therefore, reactivation of SN-38 in the tumor by β-glucuronidases may represent an important route of tumor drug activation for CPT-11.",
author = "Dodds, {Helen M.} and Tobin, {Peter J.} and Stewart, {Clinton F.} and Pam Cheshire and Suzan Hanna and Houghton, {Peter J} and Rivory, {Laurent P.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1124/jpet.102.039040",
language = "English (US)",
volume = "303",
pages = "649--655",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model

AU - Dodds, Helen M.

AU - Tobin, Peter J.

AU - Stewart, Clinton F.

AU - Cheshire, Pam

AU - Hanna, Suzan

AU - Houghton, Peter J

AU - Rivory, Laurent P.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - The anticancer drug irinotecan (CPT-11) is activated to the potent topoisomerase I inhibitor, SN-38 (7-ethyl-10-hydroxy-camptothecin), by esterases. SN-38 is in turn conjugated to the inactive SN-38 glucuronide (SN-38G). The reverse reaction is mediated by β-glucuronidases. Hence, production of SN-38 may occur through either pathway. In this study we conducted in vitro studies to examine these two reactions in neuroblastoma xenograft tumors (NB1691) and compared the rates of SN-38 production with those observed in the liver and plasma of the host SCID (severe-combined immunodeficient) mice. The rate of formation of SN-38 from CPT-11 by esterases slowed considerably during a 60-min incubation, consistent with the known deacylation-limited nature of this reaction. For xenograft tumor tissue, Km and Vmax values of 1.6 μM and 4.4 pmol/min/mg of protein, respectively, were observed. By comparison, these parameters were estimated to be 6.9 μM and 9.4 pmol/min/mg for mouse liver and 2.1 μM and 40.0 pmol/min/mg for mouse plasma, respectively. The formation of SN-38 from SN-38G was very pronounced in both liver and xenograft tumor tissue, in which it was nonsaturable (0.125-50 μM) and time-independent (0-60 min). The derived values of Vmax/Km were 0.65 μl/min/mg for the tumor and 2.12 μl/min/mg for the liver preparations. Microdialysate experiments revealed the concentrations of SN-38G and CPT-11 in tumor to be comparable. At equal substrate concentrations, production of SN-38 from SN-38G in tumor extracts was comparable with that from CPT-11. Therefore, reactivation of SN-38 in the tumor by β-glucuronidases may represent an important route of tumor drug activation for CPT-11.

AB - The anticancer drug irinotecan (CPT-11) is activated to the potent topoisomerase I inhibitor, SN-38 (7-ethyl-10-hydroxy-camptothecin), by esterases. SN-38 is in turn conjugated to the inactive SN-38 glucuronide (SN-38G). The reverse reaction is mediated by β-glucuronidases. Hence, production of SN-38 may occur through either pathway. In this study we conducted in vitro studies to examine these two reactions in neuroblastoma xenograft tumors (NB1691) and compared the rates of SN-38 production with those observed in the liver and plasma of the host SCID (severe-combined immunodeficient) mice. The rate of formation of SN-38 from CPT-11 by esterases slowed considerably during a 60-min incubation, consistent with the known deacylation-limited nature of this reaction. For xenograft tumor tissue, Km and Vmax values of 1.6 μM and 4.4 pmol/min/mg of protein, respectively, were observed. By comparison, these parameters were estimated to be 6.9 μM and 9.4 pmol/min/mg for mouse liver and 2.1 μM and 40.0 pmol/min/mg for mouse plasma, respectively. The formation of SN-38 from SN-38G was very pronounced in both liver and xenograft tumor tissue, in which it was nonsaturable (0.125-50 μM) and time-independent (0-60 min). The derived values of Vmax/Km were 0.65 μl/min/mg for the tumor and 2.12 μl/min/mg for the liver preparations. Microdialysate experiments revealed the concentrations of SN-38G and CPT-11 in tumor to be comparable. At equal substrate concentrations, production of SN-38 from SN-38G in tumor extracts was comparable with that from CPT-11. Therefore, reactivation of SN-38 in the tumor by β-glucuronidases may represent an important route of tumor drug activation for CPT-11.

UR - http://www.scopus.com/inward/record.url?scp=0036827597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036827597&partnerID=8YFLogxK

U2 - 10.1124/jpet.102.039040

DO - 10.1124/jpet.102.039040

M3 - Article

C2 - 12388647

AN - SCOPUS:0036827597

VL - 303

SP - 649

EP - 655

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -